Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ptc Therapeutics (PTCT) FCF Margin: 2012-2025

Historic FCF Margin for Ptc Therapeutics (PTCT) over the last 13 years, with Sep 2025 value amounting to -33.05%.

  • Ptc Therapeutics' FCF Margin rose 634.00% to -33.05% in Q3 2025 from the same period last year, while for Sep 2025 it was 39.64%, marking a year-over-year increase of 6010.00%. This contributed to the annual value of -14.15% for FY2024, which is 577.00% up from last year.
  • Latest data reveals that Ptc Therapeutics reported FCF Margin of -33.05% as of Q3 2025, which was up 0.88% from -33.35% recorded in Q2 2025.
  • Over the past 5 years, Ptc Therapeutics' FCF Margin peaked at 73.84% during Q1 2025, and registered a low of -104.28% during Q4 2022.
  • For the 3-year period, Ptc Therapeutics' FCF Margin averaged around -9.13%, with its median value being -16.94% (2024).
  • Its FCF Margin has fluctuated over the past 5 years, first slumped by 6,083bps in 2021, then surged by 6,981bps in 2023.
  • Quarterly analysis of 5 years shows Ptc Therapeutics' FCF Margin stood at -46.94% in 2021, then plummeted by 5,734bps to -104.28% in 2022, then soared by 6,981bps to -34.47% in 2023, then spiked by 1,863bps to -15.84% in 2024, then soared by 634bps to -33.05% in 2025.
  • Its last three reported values are -33.05% in Q3 2025, -33.35% for Q2 2025, and 73.84% during Q1 2025.